Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand

AstraZeneca104 enrolled

Overview

The purpose of this study is to determine progression-free survival of lung cancer patients who received gefitinib in clinical practice in Thailand.

Study Type

OBSERVATIONAL

Enrollment

104

Conditions

Lung Cancer

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed as having lung cancer based on histological/cytological findings * Admitted to the hospital between January 2004 and December 2008 * Treated with gefitinib for at least 3 months Exclusion Criteria: * Involvement in the planning and/or conduct of the study * Participation in another clinical study during the last 3 months

Locations (1)

Research Site

Bangkok, Thailand

Outcomes

Primary Outcomes

Progression-free survival

Time frame: median time from the first date of treatment until date of disease progression during Jan 2004- Dec 2008 or 5 years approx.

Secondary Outcomes

Time to maximum response

Time frame: Median time from the first date of treatment until the date that the disease can be maximum controlled during Jan 2004- Dec 2008 or 5 years approx.

Overall survival

Time frame: time from the first date of treatment until date of patients dead during Jan 2004- Dec 2008 or 5 years approx.

Prevalence of EGFR & KRAS mutation from laboratory result

Time frame: During Jan 2004- Dec 2008 or 5 years approx.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.